

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**WUXI BIOLOGICS (CAYMAN) INC.**

**藥明生物技術有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2269)**

**GRANT OF WAIVER  
AND  
EXTENSION OF TIME FOR APPOINTMENT OF  
INDEPENDENT NON-EXECUTIVE DIRECTOR**

Reference is made to the announcement of WuXi Biologics (Cayman) Inc. (the “**Company**”) dated November 25, 2022 (the “**Announcement**”). Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

As disclosed in the Announcement, following the passing away of Mr. Kwauk, the Company has only two independent non-executive Directors, and therefore, it does not satisfy the requirements under Rules 3.10(1), 3.10(2), 3.10A, 3.21 and 3.27A (in relation to the requirement of the nomination committee of the Company comprising a majority of independent non-executive directors) of the Listing Rules. Pursuant to Rules 3.11 and 3.23 of the Listing Rules, the Company should appoint an additional independent non-executive Director and the chairman of the Audit Committee with the Relevant Qualifications within three months after failing to meet the requirements under Rules 3.10(1), 3.10(2), 3.10A, 3.21 and 3.27A of the Listing Rules (i.e. on or before February 24, 2023).

The Company has identified and interviewed certain candidates to fill the vacancies during the past three months. As additional time is required for the Company to identify suitable candidate fulfilling the selection criteria including the Relevant Qualification as well as relevant work experience and background and complete the selection, recruitment and nomination procedures, the Company has applied to The Stock Exchange of Hong Kong Limited for and The Stock Exchange of Hong Kong Limited has granted the waiver from strict compliance with Rules 3.10(1), 3.10(2), 3.10A, 3.11, 3.21, 3.23 and 3.27A of the Listing Rules and an extension of time to May 24, 2023 for filling the vacancies.

The Company will use its best endeavor to appoint suitable candidate to fill in the vacancies of independent non-executive Director, the chairman of the Audit Committee and a member of the nomination committee of the Company. Further announcement(s) will be made as and when appropriate.

By order of the Board  
**WuXi Biologics (Cayman) Inc.**  
**Dr. Ge Li**  
*Chairman*

Hong Kong, February 28, 2023

*As at the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Dr. Ning Zhao, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller and Mr. Kenneth Walton Hitchner III as independent non-executive Directors.*

\* *For identification purpose only*